[HTML][HTML] Discovery of a highly selective chemical inhibitor of matrix metalloproteinase-9 (MMP-9) that allosterically inhibits zymogen activation

RH Scannevin, R Alexander, TM Haarlander… - Journal of Biological …, 2017 - ASBMB
Aberrant activation of matrix metalloproteinases (MMPs) is a common feature of pathological
cascades observed in diverse disorders, such as cancer, fibrosis, immune dysregulation,
and neurodegenerative diseases. MMP-9, in particular, is highly dynamically regulated in
several pathological processes. Development of MMP inhibitors has therefore been an
attractive strategy for therapeutic intervention. However, a long history of failed clinical trials
has demonstrated that broad-spectrum MMP inhibitors have limited clinical utility, which has …